(Q38222900)

31 August 2017

title

The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences (English)

1 reference

Daniel Xavier Xibille Friedmann

31 August 2017

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Mauro Keiserman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Catalin Codreanu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Rohini Handa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Eduardo Mysler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Francisco Briceño

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Servet Akar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

25 June 2014

1 reference

Expert Review of Clinical Immunology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

1049-1057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Dealing with immunogenicity of biologicals: assessment and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Are we ready for therapeutic drug monitoring of biologic therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Antibody humanization: a case of the 'Emperor's new clothes'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Recent paradigm shifts in the diagnosis and treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Subcutaneous abatacept for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Determinants of immunogenic response to protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Longterm Retention of Tumor Necrosis Factor- Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Bronchospasm associated with anti-TNF treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.926219

10.1586/1744666X.2014.926219

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24961616%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference